Fiona Kwok

1.3k total citations
19 papers, 124 citations indexed

About

Fiona Kwok is a scholar working on Molecular Biology, Nephrology and Hematology. According to data from OpenAlex, Fiona Kwok has authored 19 papers receiving a total of 124 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 8 papers in Nephrology and 6 papers in Hematology. Recurrent topics in Fiona Kwok's work include Amyloidosis: Diagnosis, Treatment, Outcomes (15 papers), Parathyroid Disorders and Treatments (7 papers) and Multiple Myeloma Research and Treatments (6 papers). Fiona Kwok is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (15 papers), Parathyroid Disorders and Treatments (7 papers) and Multiple Myeloma Research and Treatments (6 papers). Fiona Kwok collaborates with scholars based in Australia, United States and United Kingdom. Fiona Kwok's co-authors include Kenshi Suzuki, Stefan Schönland, Douglas V. Faller, Giampaolo Merlini, Deborah Berg, Ashutosh Wechalekar, Kihyun Kım, Vaishali Sanchorawala, Guohui Liu and Heather Landau and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Kidney Diseases.

In The Last Decade

Fiona Kwok

17 papers receiving 121 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fiona Kwok Australia 6 106 36 32 32 19 19 124
Sriram Ravichandran United Kingdom 7 130 1.2× 37 1.0× 32 1.0× 17 0.5× 16 0.8× 24 141
Andrew Staron United States 7 195 1.8× 44 1.2× 50 1.6× 33 1.0× 40 2.1× 24 208
Marianna Romžová Czechia 7 59 0.6× 16 0.4× 13 0.4× 12 0.4× 18 0.9× 14 148
Stefan Wörner Germany 5 78 0.7× 30 0.8× 34 1.1× 25 0.8× 32 1.7× 5 125
Dina Brauneis United States 10 281 2.7× 59 1.6× 117 3.7× 108 3.4× 64 3.4× 24 298
Nicholas F. Evageliou United States 5 106 1.0× 18 0.5× 17 0.5× 17 0.5× 11 0.6× 10 159
Méryem-Maud Farhat France 5 47 0.4× 15 0.4× 8 0.3× 41 1.3× 7 0.4× 15 107
Eugenio Piro Italy 7 49 0.5× 51 1.4× 19 0.6× 76 2.4× 5 0.3× 15 115
Debora Parracciani Italy 5 33 0.3× 32 0.9× 11 0.3× 30 0.9× 12 0.6× 6 157
Verena Barocke Germany 3 38 0.4× 46 1.3× 5 0.2× 48 1.5× 12 0.6× 3 147

Countries citing papers authored by Fiona Kwok

Since Specialization
Citations

This map shows the geographic impact of Fiona Kwok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fiona Kwok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fiona Kwok more than expected).

Fields of papers citing papers by Fiona Kwok

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fiona Kwok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fiona Kwok. The network helps show where Fiona Kwok may publish in the future.

Co-authorship network of co-authors of Fiona Kwok

This figure shows the co-authorship network connecting the top 25 collaborators of Fiona Kwok. A scholar is included among the top collaborators of Fiona Kwok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fiona Kwok. Fiona Kwok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Bart, N., Diane Fatkin, James Hare, et al.. (2024). 2024 Australia–New Zealand Expert Consensus Statement on Cardiac Amyloidosis. Heart Lung and Circulation. 33(4). 420–442. 2 indexed citations
3.
Emerson, Peter, Karen Byth, Anita Boyd, et al.. (2024). Diagnostic and Prognostic Value of the Left Atrial Myopathy Evaluation in Cardiac Amyloidosis Using Echocardiography. ESC Heart Failure. 11(6). 4139–4147. 5 indexed citations
4.
Gibbons, A.J., N. Anderson, Fiona Kwok, et al.. (2023). Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-Based Chemotherapy. Blood. 142(Supplement 1). 2030–2030. 1 indexed citations
5.
Boyd, Anita, et al.. (2023). A novel echocardiographic risk score for light-chain amyloidosis. European Heart Journal Open. 3(3). oead040–oead040. 5 indexed citations
6.
Sanchorawala, Vaishali, Ashutosh Wechalekar, Kihyun Kım, et al.. (2023). Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib‐dexamethasone versus physician's choice. American Journal of Hematology. 98(5). 720–729. 4 indexed citations
7.
Kastritis, Efstathios, Jeffrey Matous, Jesús G. Berdeja, et al.. (2023). PB2122: A PHASE 1/2 MULTI-CENTER, DOSE-FINDING STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PK AND EFFICACY OF ZN-D5, A NOVEL BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY AL AMYLOIDOSIS. HemaSphere. 7(S3). e5544426–e5544426. 1 indexed citations
8.
Taylor, Mark, M Hasib Sidiqi, James Hare, et al.. (2022). Current approaches to the diagnosis and management of amyloidosis. Internal Medicine Journal. 52(12). 2046–2067. 7 indexed citations
9.
Kwok, Fiona, et al.. (2022). Correlation of Quantitative 99mTc DPD Scintigraphy With Echocardiographic Alterations in Left Atrial Parameters in Transthyretin Amyloidosis. Heart Lung and Circulation. 31(6). 804–814. 2 indexed citations
10.
Boyd, Anita, David Richards, Graeme J. Stewart, et al.. (2022). Alterations in multi-layer strain in AL amyloidosis. Amyloid. 29(2). 128–136. 4 indexed citations
11.
Kwok, Fiona, et al.. (2021). Correlation Between Quantitative Uptake of 99mTC-DPD and Echocardiographic Parameters in Cardiac ATTR: A Novel Follow-Up Strategy. Frontiers in Cardiovascular Medicine. 8. 663929–663929. 3 indexed citations
12.
Dispenzieri, Angela, Efstathios Kastritis, Ashutosh Wechalekar, et al.. (2021). A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis. Leukemia. 36(1). 225–235. 35 indexed citations
13.
14.
Kastritis, Efstathios, Angela Dispenzieri, Ashutosh Wechalekar, et al.. (2020). Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.. Journal of Clinical Oncology. 38(15_suppl). 8546–8546. 7 indexed citations
15.
Dispenzieri, Angela, Ashutosh Wechalekar, Stefan Schönland, et al.. (2019). Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). Blood. 134(Supplement_1). 139–139. 32 indexed citations
16.
Li, Jennifer, et al.. (2018). Cryoglobulinemic Glomerulonephritis Associated With Nodal and Renal Infiltration by T-Cell Lymphoma of T-Follicular Helper Phenotype: A Case Report. American Journal of Kidney Diseases. 72(4). 606–611. 3 indexed citations
17.
Mollee, Peter, Fiona Kwok, JA Gilbertson, et al.. (2015). LECT2 Amyloidosis: not just a Hispanic disease. Clinical Lymphoma Myeloma & Leukemia. 15. e186–e186. 2 indexed citations
18.
Paik, Jisun, Fiona Kwok, Audrey Seamons, et al.. (2015). Effects of murine norovirus on atherosclerosis in ldlr(-/-) mice depends on the timing of infection.. PubMed. 65(2). 114–22. 5 indexed citations
19.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sriram Ravichandran Breakdown of academic impact, for papers by Andrew Staron Breakdown of academic impact, for papers by Marianna Romžová Breakdown of academic impact, for papers by Stefan Wörner Breakdown of academic impact, for papers by Dina Brauneis Breakdown of academic impact, for papers by Nicholas F. Evageliou Breakdown of academic impact, for papers by Méryem-Maud Farhat Breakdown of academic impact, for papers by Eugenio Piro Breakdown of academic impact, for papers by Debora Parracciani Breakdown of academic impact, for papers by Verena Barocke
Rankless by CCL
2026